Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buspirone for Levodopa-Induced Dyskinesia in Parkinson's Disease
NCT02617017Phase 3Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Jun 2016
- Primary completion
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of buspirone in levodopa-induced dyskinesia (LID), sponsored by Assistance publique - Hôpitaux de Paris. Started Jun 2016; status: completed.
02
Drugs
buspirone
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on NCT02617017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02617017.